Program
SIM0270
A development code. Also written as “[14C] SIM0270 Oral Preparation”.
Its studies are mostly in Breast Neoplasms, led by Simcere Pharmaceutical Group.
Furthest: phase 3, since Nov 5, 20245 company-led studies, 4 open or runningNext primary completion: Aug 31, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Simcere Pharmaceutical Group | 54 open or running | phase 3since Nov 5, 2024 | Mar 7, 2022 | Aug 31, 2028phase 3 · NCT06680921 |
Also a collaborator on its studies: nanjing-zaiming-pharmaceutical-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 7, 2022First study: phase 1 study in Breast NeoplasmsFirst studyNCT05293964 · 214 enrolled · China
- Jul 16, 2024Phase 1 study in Healthy ParticipantsNCT06536036 · 16 enrolled · China
- Oct 21, 2024Phase 1 study in Healthy ParticipantsNCT06654791 · 6 enrolled · China
- Nov 5, 2024Phase 3 study in Breast NeoplasmsNCT06680921 · 482 enrolled · China
- Jan 2, 2026Phase 1 study in Healthy Adult ParticipantsNCT07357610 · 60 planned · China
Ahead
- Aug 31, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT06680921
TargetBeta
ESR1 →read by rule
“SIM0270 is an oral, selective estrogen receptor degrader (SERD)”study text, by rule · the study
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07357610Healthy Adult Participants · China | 1 | Recruiting | Oct 30, 2026 | 60 |
| NCT06680921Breast Neoplasms · China | 3 | Active, not recruiting | Aug 31, 2028 | 482 |
| NCT06654791Healthy Participants · China | 1 | Active, not recruiting | Mar 31, 2025 | 6 |
| NCT06536036Healthy Participants · China | 1 | Completed | Oct 16, 2024 | 16 |
| NCT05293964Breast Neoplasms · China | 1 | Active, not recruiting | Dec 31, 2024 | 214 |
How it is read
Names in the registry
- “SIM0270”, 4 entries
- “[14C] SIM0270 Oral Preparation”, 1 entry
Codes read as this program: SIM0270.
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.